To read the full article sign up for free or sign in.

Chinese biotechs apply new tech to accelerate drug R&D for COVID-19

Feb. 25, 2020

BEIJING – As the clock ticks on COVID-19’s spread, Chinese biotech companies are hoping to unleash the power of cloud computing and artificial intelligence to find a cure for the virus.

BioWorld BioWorld Asia Coronavirus China

Today's news in brief

BioWorld

BioWorld briefs for April 7, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for April 7, 2025.

Caution tape displaying US flag, tariffs

Biopharma exempt from US reciprocal tariffs, but not untouched

BioWorld

At first glance, it appears that biopharmaceuticals dodged the latest U.S. tariff bullet; med-tech, not so much. According to the executive order President Donald...

PFA non-inferior, even superior, to cryoablation for paroxysmal AF

BioWorld MedTech

Pulsed field ablation using Boston Scientific Corp.’s Farapulse system was non-inferior and even superior, slightly, to Medtronic plc’s Artic Front Advance...

ABL lands £2B deal with GSK based on BBB passing drug platform

BioWorld

ABL Bio Inc. announced April 7 that it sealed a potential £2.075 billion (US$2.65 billion) license deal with GSK plc, granting GSK global rights to use ABL’s...